Chargement en cours...

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients

BACKGROUND: Bezlotoxumab has been shown to prevent recurrent episodes of C. difficile infection (CDI) in high risk patients. Current studies define therapeutic efficacy within the first 12 weeks when the risk of recurrence is greatest. However, the risk of recurrent CDI can occur beyond the 12-week...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Open Forum Infect Dis
Auteurs principaux: Perreault, Sarah, Schiffer, Molly, Ruggero, Michael, McManus, Dayna, Topal, Jeffrey E
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777471/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.921
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!